MDMB-FUBICA

MDMB-FUBICA
Legal status
Legal status
Identifiers
CAS Number
ChemSpider
Chemical and physical data
Formula C23H25FN2O3
Molar mass 396.46 g·mol−1
3D model (JSmol)

MDMB-FUBICA is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug.

It was first detected by the EMCDDA in Sweden in February 2015.[1] It is often sold in e-liquid form for use in a electronic cigarette.[2]

Side effects

MDMB-FUBICA's indazole analogue MDMB-FUBINACA has been linked to at least 1000 hospitalisations and 40 deaths as a consequence of intoxication as of March 2015.[3]

Legality

MDMB-FUBICA is banned in Sweden.[4]

See also

References

  1. ↑ "HAMAROSAN: 2015. ÉVI EURÓPAI KÁBÍTÓSZER - JELENTÉS" (PDF). Hungarian National Focal Point (NFP). June 2015. Retrieved 23 July 2015.
  2. ↑ Peace, Michelle R.; Krakowiak, Rose I.; Wolf, Carl E.; Poklis, Alphonse; Poklis, Justin L. (February 2017). "Identification of MDMB-FUBINACA in commercially available e-liquid formulations sold for use in electronic cigarettes". Forensic Science International. 271: 92–97. doi:10.1016/j.forsciint.2016.12.031. ISSN 0379-0738. PMC 5511053. PMID 28076838.
  3. ↑ "Очередная жертва спайса". Federal Drug Control Service of the Russian Federation. 17 March 2015. Retrieved 24 July 2015.
  4. ↑ "23 nya ämnen kan klassas som narkotika eller hälsofarlig vara". Folkhälsomyndigheten. 1 June 2015. Retrieved 24 July 2015.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.